Metformin Use Correlates with Reduced Risk of Gallstones in Diabetic Patients: A 12-Year Follow-up Study

Kuan-Fu Liao; Hsun-Yang Chuang; Shih-Wei Lai
October 2017
Frontiers in Pharmacology;10/24/2017, p1
Academic Journal
Objective: Few studies are available on the association between gallstones and metformin use. The objective of the study was to determine whether metformin use is associated with gallstones. Methods: A population-based retrospective cohort study was conducted using the database of the Taiwan National Health Insurance Program. Subjects of newly diagnosed diabetes mellitus were included from 2002 to 2013. The metformin-exposure group was defined as ≥29 cumulative defined daily dose (DDD) of metformin use. The un-exposure group was defined as <29 cumulative DDD of metformin use. The major endpoint was a new diagnosis of gallstones during the follow-up period. A multivariable Cox proportional hazards regression model was used to evaluate the hazard ratio (HR) and 95% confidence interval (CI) of gallstones associated with metformin use. Results: After controlling for potential confounders, the adjusted HRs of gallstones were 1.11 (95%CI: 0.84-1.46) for subjects with metformin dosage of 29-180 cumulative DDD, and 0.57 (95%CI: 0.42-0.78) for subjects with metformin dosage >180 cumulative DDD, compared with the un-exposure group. Conclusion: Long-term use of metformin is associated with reduced risk of gallstones.


Related Articles

  • New listings on Australian PBS.  // PharmacoEconomics & Outcomes News;Jan2014, Issue 694, p9 

    The article reports that patients with diabetes will receive alogliptin/metformin through the Pharmaceutical Benefits Scheme (PBS) of the Australian government starting February 1, 2014.

  • Metformin may protect against intrahepatic cholangiocarcinoma in diabetes.  // Endocrine Today;Jan2013, Vol. 11 Issue 1, p18 

    The article reports on a study which found that patients with diabetes who received metformin were at reduced risk for intrahepatic cholangiocarcinoma, whereas biliary tract disease, cirrhosis, diabetes and smoking increased that risk.

  • UTSTAT.  // Urology Times;Aug2013, Vol. 41 Issue 9, p11 

    Statistics are presented on the percentage of mortality risk for prostate cancer every six months of use of metformin.

  • Diabetes treatment, prevention research shows promise. Coopman, Robert // Chain Drug Review;11/23/2015, Vol. 37 Issue 19, p26 

    The article reports on the progress of diabetes research as they pertain to the efficacy of metformin for treating cardiovascular disease in patients with or without diabetes and the possibility of islet cell transplantation and regeneration.

  • Common diabetes drug linked to vitamin deficiency.  // Romanian Journal of Medical Practice;2010, Vol. 5 Issue 2, p87 

    The article reports on the findings of a study by Dutch scientists led by Coen Stehouwer of Maastrict University Medical Center which suggest that regular checking of vitamin B-12 levels during long-term metformin treatment for diabetes should be considered to prevent deficiency and its effects.

  • Renal Risks Lower with Metformin Use.  // Renal & Urology News;Feb2012, Vol. 11 Issue 2, p22 

    The article reports on the health effects of the use of metformin as first-time treatment for patients with type 2 diabetes.

  • Scant evidence on metformin's effectiveness in type 2 diabetes. Perry, Thomas L. // BMJ: British Medical Journal;5/23/2015, Vol. 350 Issue 8009, ph2650 

    A letter to the editor in response to the article "Using Metformin in the Presence of Renal Disease" in a 2015 issue is presented.

  • Diabetes drug lowers PCa-specific, all-cause mortality. Krader, Cheryl Guttman // Urology Times;Aug2013, Vol. 41 Issue 9, p11 

    The article focuses on a retrospective study regarding the effectiveness of metformin on diabetic men diagnosed with prostate cancer. It says that the said drug helps in reducing cancer-specific and all-cause mortality, an in exposure to the said drug increases the cumulative duration of...

  • Acarbose noninferior to metformin in type 2 diabetes.  // Endocrine Today;Nov2013, Vol. 11 Issue 11, p9 

    The article discusses a research study published in an issue of the journal "The Lancet" which found that patients with type 2 diabetes treated with acarbose experienced similar improvements in HbAlc as those treated with metformin.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics